Thieler Law Corp advises investors with losses exceeding $100,000 of the November 26, 2018 lead plaintiff deadline in a class action lawsuit filed against Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) (“Alnylam” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased Alnylam Pharmaceuticals Inc securities between February 22, 2017 and July 19, 2018, have until November 26, 2018 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Alnylam Pharmaceuticals Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection; and as a result, Alnylam’s public statements were materially false and misleading at all relevant times.

On September 12, 2018, an analyst for Nomura/Instinet, Christopher Marai revealed that a review document released by the FDA Center for Drug Evaluation and Research "highlights greater risk" with respect to certain trials of Alnylam's ONPATTRO (patisiran) lipid complex injection, as well as "a limited market opportunity in TTRcardiomyopathy, and a potential platform safety risk."  In particularly, Christopher Marai asserted that "[t]he document highlights FDA reviewers' concerns over cardiac deaths in patients treated with ONPATTRO and suggests that the drug should be limited to patients with polyneuropathy only (i.e., not patients with cardiac manifestations and polyneuropathy).  Furthermore, we believe some comments on the lack of cardiac efficacy call into question claims made by [Alnylam] in this regard." 

Following this news, NASDAQ: SONS fell sharply during intraday trading on September 12, 2018.

If you were negatively impacted by your investment in Alnylam Pharmaceuticals Inc securities between February 22, 2017 and July 19, 2018 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185